Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O75665

UPID:
OFD1_HUMAN

ALTERNATIVE NAMES:
Oral-facial-digital syndrome 1 protein; Protein 71-7A

ALTERNATIVE UPACC:
O75665; B9ZVU5; O75666; Q4VAK4

BACKGROUND:
The protein OFD1, with alternative names Oral-facial-digital syndrome 1 protein and Protein 71-7A, is integral to centriole and cilium function. It ensures proper centriole length and recruits specific proteins for cilium formation, a critical component for cellular signaling and development. OFD1's role in autophagy and ciliogenesis regulation is vital for maintaining cellular homeostasis and developmental processes.

THERAPEUTIC SIGNIFICANCE:
Mutations in OFD1 are associated with a spectrum of disorders, including various syndromes that affect facial, digital, and neurological development. The exploration of OFD1's function offers a promising avenue for developing therapeutic strategies aimed at these complex conditions, underscoring the importance of research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.